ACRS
Aclaris Therapeutics, Inc.Company Information
- Company Name
- Aclaris Therapeutics, Inc.
- CIK
- CIK0001557746
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ACRS: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ACRS
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-11-19
- Last sale
- 2026-04-23
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 300,000
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 106,034,675
- Shares outstanding
- 128,810,050
- Ownership
- 82.32%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- -1.31%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 19 | 29 | 20 | 25 | 25 | 30 | 25 | 48 | 23 | 36 | 40 | 39 | ||||||
| Available For Sale Securities Debt Securities Current | 72 | 77 | 71 | 71 | 74 | 75 | 89 | 80 | 88 | 92 | 79 | 64 | ||||||
| Accounts Receivable Net Current | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | - | - | - | - | 4 | 3 | 12 | 4 | 6 | 7 | 9 | 20 | ||||||
| Assets Current | 98 | 110 | 96 | 101 | 104 | 109 | 126 | 132 | 118 | 135 | 129 | 123 | ||||||
| Available For Sale Securities Debt Securities Noncurrent | 79 | 85 | 61 | 71 | 81 | 85 | 90 | 46 | 39 | 33 | 63 | 84 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | ||||||
| Other Assets Noncurrent | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 3 | ||||||
| Intangible Assets Net Excluding Goodwill | - | - | - | - | - | - | - | - | - | - | 0 | 7 | ||||||
| Assets | 180 | 199 | 160 | 176 | 189 | 198 | 220 | 182 | 161 | 174 | 197 | 218 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 16 | 15 | 13 | 9 | 9 | 6 | 5 | 8 | 7 | 11 | 9 | 10 | ||||||
| Accrued Liabilities Current | 6 | 6 | 9 | 10 | 11 | 9 | 20 | 5 | 6 | 7 | 19 | 15 | ||||||
| Contract With Customer Liability Current | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | - | - | - | - | ||||||
| Other Liabilities Current | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | - | ||||||
| Operating Lease Liability Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Current | - | - | - | - | - | - | - | - | - | - | 2 | 2 | ||||||
| Liabilities Current | 28 | 27 | 29 | 26 | 27 | 22 | 32 | 19 | 16 | 20 | 31 | 27 | ||||||
| Other Liabilities Noncurrent | 1 | 1 | 2 | 2 | 2 | 4 | 4 | 2 | 2 | 3 | 3 | 2 | ||||||
| Contract With Customer Liability Noncurrent | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | - | - | - | - | ||||||
| Business Combination Contingent Consideration Liability Noncurrent | 11 | 11 | 11 | 11 | 11 | 9 | 9 | 10 | 9 | 9 | 6 | 33 | ||||||
| Deferred Income Tax Liabilities Net | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Liabilities | 55 | 55 | 57 | 55 | 57 | 54 | 65 | 52 | 27 | 32 | 40 | 62 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 1,134 | 1,131 | 1,070 | 1,067 | 1,065 | 1,062 | 1,058 | 936 | 933 | 930 | 928 | 927 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | -0 | -0 | -0 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -1,009 | -988 | -968 | -948 | -933 | -918 | -903 | -806 | -799 | -788 | -771 | -769 | ||||||
| Stockholders Equity | 125 | 144 | 103 | 120 | 132 | 144 | 156 | 130 | 134 | 142 | 157 | 156 | ||||||
| Liabilities And Stockholders Equity | 180 | 199 | 160 | 176 | 189 | 198 | 220 | 182 | 161 | 174 | 197 | 218 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 400 | 400 | 400 | 400 | 400 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 140 | 140 | 120 | 108 | 108 | 108 | 108 | 71 | 71 | 71 | 71 | 71 | ||||||
| Shares Outstanding | 140 | 140 | 120 | 108 | 108 | 108 | 108 | 71 | 71 | 71 | 71 | 71 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAclaris Therapeutics, Inc. (ACRS) — SEC Financial Statements & Analysis
Aclaris Therapeutics, Inc. (ACRS) is a pharmaceutical preparations company, incorporated in DE. Aclaris Therapeutics, Inc. trades on Nasdaq as: ACRS. Aclaris Therapeutics, Inc. (ACRS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Aclaris Therapeutics, Inc. carries a market cap of $755.08M, a P/E ratio of -9.97x, a P/B ratio of 6.06x, a P/S ratio of 91.87x, an enterprise value of $735.91M, and an EV/EBITDA multiple of -8.57x. On profitability, it posts a gross margin of 79.52%, an operating margin of -1050.16%, a net margin of -921.50%, a Return on Equity (ROE) of -59.10%, a Return on Assets (ROA) of -41.07%, and a Return on Invested Capital (ROIC) of -81.33%. Per share, it reports EPS of $-0.53, diluted EPS of $-0.53, free cash flow per share of $-0.44, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -51.04% year-over-year, net income growth of -43.75% year-over-year, and EPS growth of -51.70% year-over-year. On the balance sheet, it maintains a current ratio of 3.46x, a quick ratio of 3.46x, working capital of $69.52M, a debt-to-equity ratio of 0.44x, a debt ratio of 0.31, free cash flow of $-62.18M (TTM), and net debt of $-19.17M. Figures sourced from SEC EDGAR.
- Market Cap
- $755.08M
- P/E TTM
- -9.97x
- EPS TTM
- $-0.53
- P/B TTM
- 6.06x
- ROE TTM
- -59.10%
- ROA TTM
- -41.07%
- Debt To Equity
- 0.44x
- Free Cash Flow TTM
- $-62.18M
- Net Revenue TTM Growth 1Y
- -51.04%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Aclaris Therapeutics, Inc. in?
Aclaris Therapeutics, Inc. (ACRS) operates in the Pharmaceutical Preparations industry.
What exchange does ACRS trade on?
Aclaris Therapeutics, Inc. (ACRS) trades on the Nasdaq.
Where is Aclaris Therapeutics, Inc. incorporated?
Aclaris Therapeutics, Inc. is incorporated in DE.
When was Aclaris Therapeutics, Inc. (ACRS)'s most recent SEC filing?
Aclaris Therapeutics, Inc. (ACRS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is ACRS's market cap?
Aclaris Therapeutics, Inc. (ACRS) has a market capitalization of $755.08M as of 2026-06-30.
What is ACRS's EPS (earnings per share)?
Aclaris Therapeutics, Inc. (ACRS)'s trailing twelve month EPS is $-0.53 as of 2026-06-30.
What is ACRS's ROE (return on equity)?
Aclaris Therapeutics, Inc. (ACRS)'s trailing twelve month Return on Equity (ROE) is -59.10% as of 2026-06-30.
What is ACRS's ROA (return on assets)?
Aclaris Therapeutics, Inc. (ACRS)'s trailing twelve month Return on Assets (ROA) is -41.07% as of 2026-06-30.
What is ACRS's ROIC (return on invested capital)?
Aclaris Therapeutics, Inc. (ACRS)'s trailing twelve month Return on Invested Capital (ROIC) is -81.33% as of 2026-06-30.
What is ACRS's EV/EBITDA?
Aclaris Therapeutics, Inc. (ACRS)'s trailing twelve month EV/EBITDA is -8.57x as of 2026-06-30.